Weekly reads: KRAS G12C, eLife journal controversy, bird iPSCs
If you’ve never heard of the KRAS G12C mutation, it’s a particularly frightening mutation present in numerous cancers. Like the MYC oncogene, many people view mutations in RAS as undruggable, but new efforts show some glimmers of hope. The drug Sotorasib has been approved by the FDA to target the KRAS G12C mutation. Here’s a […]
Weekly reads: KRAS G12C, eLife journal controversy, bird iPSCs Read More »